Product nameHepG2 nuclear extract lysate (acetaldehyde treated)
See all HepG2 lysates
General notesCell line: HepG2 (Human hepatocellular carcinoma).
Cells were cultured in medium supplemented with 200 µM Acetaldehyde for 4 hours at 37°C immediately prior to harvesting.
We recommend aliquoting the extracts into single-use fractions and then storing them.
Tested applicationsSuitable for: EMSA, WBmore details
Storage instructionsShipped on dry ice. Upon delivery aliquot and store at -80ºC. Avoid freeze / thaw cycles.
Storage bufferpH: 7.90
Constituents: 0.75% Potassium chloride, 0.009% PMSF, 0.01% Magnesium chloride, 0.008% DTT, 0.48% HEPES, 20% Glycerol
Concentration information loading...
BackgroundHepatitis B virus (HBV) is the major cause of acute and chronic hepatitis, leading to progressive development of necroinflammatory changes in the liver, which can result in cirrhosis and hepatocellular carcinoma. Although the development of an effective vaccine to prevent HBV infection has shown promising results and should lead to its eventual eradication, antiviral chemotherapy remains the only effective method to prevent the progression of the disease in chronic carriers. Therefore, the development of new antiretroviral agents active against HBV is needed. HepG2 cells have an epithelial morphology and are thought to be a very useful model to study HBV virus replication via transfection. Cells are also used for cancer and apoptosis studies (in particular signalling pathway studies).
Our Abpromise guarantee covers the use of ab14661 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|EMSA||Use at an assay dependent dilution.|
|WB||Use at an assay dependent dilution.|
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab14661 has not yet been referenced specifically in any publications.